Autopsy report · NCT03868943
Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma
Cause of deathFunding or business
“Axsome has conducted a review of the ongoing IST program and are unable to continue supporting this study”
Life of this trial
- Registered 1 year 11 months before it started.
- Ran for about 10 months before it stopped.
- 2 participants enrolled.
- Results were posted on the registry 3 years 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Wake Forest University Health Sciences
- Sponsor type
- University, hospital or other
- Conditions
- Glioma; Glioblastoma
- Interventions
- Soliramfetol
- Participants
- 2
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.